Elevai e-commerce portal webview of the shopping cart and physician finder tool
Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market
March 18, 2024 08:30 ET | Elevai Labs Inc.
Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical
NurExone logo2.png
NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel
March 08, 2024 16:05 ET | NurExone Biologic Inc
NurExone establishing State-of-the-Art Research and Development Facility on Technion Campus in Israel
NurExone logo2.png
NurExone’s Intellectual Property Portfolio Expands
February 20, 2024 16:05 ET | NurExone Biologic Inc
NurExone's Intellectual Property portfolio is expanding to encompass processes and compositions related to exosomes in large-scale production
NurExone logo2.png
NurExone Launches Licensing Efforts for ExoTherapy Platform
February 14, 2024 16:20 ET | NurExone Biologic Inc
NurExone Biologic launches licensing efforts for its ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.
NurExone logo2.png
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant
February 02, 2024 16:05 ET | NurExone Biologic Inc
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant for its groundbreaking ExoPTEN product
800 px horizontal logo.png
ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office
January 24, 2024 08:30 ET | Elevai Labs Inc.
ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office
800 px horizontal logo.png
ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach
January 17, 2024 08:30 ET | Elevai Labs Inc.
ELEVAI Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach
800 px horizontal logo.png
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
January 16, 2024 08:30 ET | Elevai Labs Inc.
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
NurExone logo2.png
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
January 05, 2024 08:30 ET | NurExone Biologic Inc
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
800 px horizontal logo.png
ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences
January 02, 2024 09:15 ET | Elevai Labs Inc.
ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences